Global Blood Therapeutics (GBT), now a part of Pfizer, is a leading company in the healthcare industry, focusing on addressing the challenges of major respiratory illnesses such as COVID-19, influenza, and RSV. With a culture centered on easing the healthcare burden, GBT is dedicated to mitigating the impact of these diseases on global health systems. Their technical prowess and industry leadership are demonstrated by their strategic approach to managing the "triple-demic", thereby ensuring resources are not diverted away from other patients in need.